February 6, 2025
Current antiviral treatment course is inadequate for high-risk COVID-19

Molnupiravir’s impact on SARS-CoV-2 response in at-risk outpatients.
Continue reading Current antiviral treatment course is inadequate for high-risk COVID-19 on Tech Explorist…
Read More

About The Author

Leave a Reply

Your email address will not be published. Required fields are marked *